BDSX Quote, Financials, Valuation and Earnings

ProPhase Labs, Inc. has a net margin of -40.04% compared to Biodesix, Inc.'s net margin of -774.52%. Biodesix, Inc.'s return on equity of -333.87% beat ProPhase Labs, Inc.'s return on equity of -90.24%.

Biodesix, Inc. has a consensus price target of $32.50, signalling upside risk potential of 299.26%. On the other hand ProPhase Labs, Inc. has an analysts' consensus of $13.80 which suggests that it could grow by 10099.56%. Given that ProPhase Labs, Inc. has higher upside potential than Biodesix, Inc., analysts believe ProPhase Labs, Inc. is more attractive than Biodesix, Inc..

Biodesix, Inc. has a beta of 0.625, which suggesting that the stock is 37.529% less volatile than S&P 500. In comparison ProPhase Labs, Inc. has a beta of -0.657, suggesting its less volatile than the S&P 500 by 165.684%.

Biodesix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biodesix, Inc. pays -- of its earnings as a dividend. ProPhase Labs, Inc. pays out -- of its earnings as a dividend.

Biodesix, Inc. quarterly revenues are $21.8M, which are larger than ProPhase Labs, Inc. quarterly revenues of $883K. Biodesix, Inc.'s net income of -$8.7M is lower than ProPhase Labs, Inc.'s net income of -$6.8M. Notably, Biodesix, Inc.'s price-to-earnings ratio is -- while ProPhase Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biodesix, Inc. is 7.82x versus 0.93x for ProPhase Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Thermo Fisher Scientific, Inc. has a net margin of -40.04% compared to Biodesix, Inc.'s net margin of 14.58%. Biodesix, Inc.'s return on equity of -333.87% beat Thermo Fisher Scientific, Inc.'s return on equity of 13.15%.

Biodesix, Inc. has a consensus price target of $32.50, signalling upside risk potential of 299.26%. On the other hand Thermo Fisher Scientific, Inc. has an analysts' consensus of $619.96 which suggests that it could grow by 6.81%. Given that Biodesix, Inc. has higher upside potential than Thermo Fisher Scientific, Inc., analysts believe Biodesix, Inc. is more attractive than Thermo Fisher Scientific, Inc..

Biodesix, Inc. has a beta of 0.625, which suggesting that the stock is 37.529% less volatile than S&P 500. In comparison Thermo Fisher Scientific, Inc. has a beta of 0.899, suggesting its less volatile than the S&P 500 by 10.144%.

Biodesix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Thermo Fisher Scientific, Inc. offers a yield of 0.29% to investors and pays a quarterly dividend of $0.43 per share. Biodesix, Inc. pays -- of its earnings as a dividend. Thermo Fisher Scientific, Inc. pays out 9.43% of its earnings as a dividend. Thermo Fisher Scientific, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Biodesix, Inc. quarterly revenues are $21.8M, which are smaller than Thermo Fisher Scientific, Inc. quarterly revenues of $11.1B. Biodesix, Inc.'s net income of -$8.7M is lower than Thermo Fisher Scientific, Inc.'s net income of $1.6B. Notably, Biodesix, Inc.'s price-to-earnings ratio is -- while Thermo Fisher Scientific, Inc.'s PE ratio is 33.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biodesix, Inc. is 7.82x versus 5.04x for Thermo Fisher Scientific, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Veracyte, Inc. has a net margin of -40.04% compared to Biodesix, Inc.'s net margin of 14.51%. Biodesix, Inc.'s return on equity of -333.87% beat Veracyte, Inc.'s return on equity of 2.52%.

Biodesix, Inc. has a consensus price target of $32.50, signalling upside risk potential of 299.26%. On the other hand Veracyte, Inc. has an analysts' consensus of $47.10 which suggests that it could fall by -1.36%. Given that Biodesix, Inc. has higher upside potential than Veracyte, Inc., analysts believe Biodesix, Inc. is more attractive than Veracyte, Inc..

Biodesix, Inc. has a beta of 0.625, which suggesting that the stock is 37.529% less volatile than S&P 500. In comparison Veracyte, Inc. has a beta of 1.829, suggesting its more volatile than the S&P 500 by 82.869%.

Biodesix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biodesix, Inc. pays -- of its earnings as a dividend. Veracyte, Inc. pays out -- of its earnings as a dividend.

Biodesix, Inc. quarterly revenues are $21.8M, which are smaller than Veracyte, Inc. quarterly revenues of $131.9M. Biodesix, Inc.'s net income of -$8.7M is lower than Veracyte, Inc.'s net income of $19.1M. Notably, Biodesix, Inc.'s price-to-earnings ratio is -- while Veracyte, Inc.'s PE ratio is 125.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biodesix, Inc. is 7.82x versus 7.67x for Veracyte, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

XWELL, Inc. has a net margin of -40.04% compared to Biodesix, Inc.'s net margin of -2.87%. Biodesix, Inc.'s return on equity of -333.87% beat XWELL, Inc.'s return on equity of -224.93%.

Biodesix, Inc. has a consensus price target of $32.50, signalling upside risk potential of 299.26%. On the other hand XWELL, Inc. has an analysts' consensus of -- which suggests that it could grow by 775%. Given that XWELL, Inc. has higher upside potential than Biodesix, Inc., analysts believe XWELL, Inc. is more attractive than Biodesix, Inc..

Biodesix, Inc. has a beta of 0.625, which suggesting that the stock is 37.529% less volatile than S&P 500. In comparison XWELL, Inc. has a beta of 1.227, suggesting its more volatile than the S&P 500 by 22.697%.

Biodesix, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biodesix, Inc. pays -- of its earnings as a dividend. XWELL, Inc. pays out -- of its earnings as a dividend.

Biodesix, Inc. quarterly revenues are $21.8M, which are larger than XWELL, Inc. quarterly revenues of $7.3M. Biodesix, Inc.'s net income of -$8.7M is lower than XWELL, Inc.'s net income of -$211K. Notably, Biodesix, Inc.'s price-to-earnings ratio is -- while XWELL, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biodesix, Inc. is 7.82x versus 0.15x for XWELL, Inc.. Usually stocks with elevated PS ratios are considered overvalued.